REGENXBIO Ownership | Who Owns REGENXBIO?
REGENXBIO Ownership Summary
REGENXBIO is owned by 57.91% institutional investors, 8.01% insiders, and 34.08% retail investors. Blackrock is the largest institutional shareholder, holding 18.83% of RGNX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.94% of its assets in REGENXBIO shares.
RGNX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | REGENXBIO | 57.91% | 8.01% | 34.08% |
| Sector | Healthcare Stocks | 232.63% | 10.66% | -143.29% |
| Industry | Biotech Stocks | 382.12% | 10.42% | -292.54% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock | 8.61M | 18.83% | $100.73M |
| Blackrock funding, inc. /de | 5.76M | 11.14% | $82.90M |
| Redmile group | 4.69M | 9.12% | $45.29M |
| Jpmorgan chase | 3.55M | 6.87% | $51.17M |
| Vanguard group | 3.37M | 6.53% | $48.59M |
| Morgan stanley | 2.01M | 3.90% | $29.01M |
| State street | 1.98M | 3.86% | $19.15M |
| Goldman sachs group | 1.79M | 3.45% | $25.71M |
| Millennium management | 1.32M | 2.60% | $10.22M |
| Assenagon asset management | 1.16M | 2.24% | $16.71M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Sonic gp | 453.08K | 10.94% | $5.30M |
| 22nw, lp | 923.68K | 5.60% | $13.30M |
| Redmile group | 4.69M | 4.41% | $45.29M |
| Aquilo capital management | 346.30K | 4.04% | $2.68M |
| Lion point capital, lp | 57.75K | 3.17% | $557.29K |
| Propel bio management | 116.90K | 1.44% | $1.68M |
| Integral health asset management | 1.10M | 0.72% | $10.62M |
| Ghost tree capital | 170.00K | 0.62% | $1.99M |
| Archpoint investors | 223.53K | 0.59% | $2.16M |
| Gsk | 271.46K | 0.49% | $3.91M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Millennium management | 1.32M | 0.01% | 1.06M |
| Blackrock | 8.61M | 0.00% | 1.01M |
| Assenagon asset management | 1.16M | 0.02% | 454.98K |
| Norges bank | 449.40K | 0.00% | 449.40K |
| Invenomic capital management lp | 426.90K | 0.20% | 426.90K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock funding, inc. /de | 5.76M | 0.00% | -614.08K |
| Balyasny asset management | 797.10K | 0.01% | -601.40K |
| Avidity partners management lp | 532.00K | 0.40% | -600.56K |
| Aquilo capital management | 346.30K | 4.04% | -584.41K |
| Adage capital partners gp | - | - | -500.00K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Norges bank | 449.40K | 0.00% | 449.40K | $3.47M |
| Invenomic capital management lp | 426.90K | 0.20% | 426.90K | $4.12M |
| Gsk | 271.46K | 0.49% | 271.46K | $3.91M |
| Nebula research & development | 151.29K | 0.11% | 151.29K | $1.24M |
| Susquehanna portfolio strategies | 133.56K | 0.02% | 133.56K | $1.29M |
Sold Out
| Holder | Change |
|---|---|
| Tradewinds capital management | -3.00 |
| Mendota financial group | -4.00 |
| Smartleaf asset management | -5.00 |
| Nelson, van denburg & campbell wealth management group | -8.00 |
| Innealta capital | -8.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 125 | -28.98% | 29,932,803 | -27.67% | 57 | 0.90% | 60 | -28.57% | 40 | -23.08% |
| Sep 30, 2025 | 168 | - | 41,425,722 | -1.46% | 80 | 1.21% | 77 | -9.41% | 51 | 4.08% |
| Jun 30, 2025 | 167 | -1.18% | 42,031,093 | 1.56% | 81 | 1.26% | 84 | -2.33% | 49 | -5.77% |
| Mar 31, 2025 | 171 | -6.04% | 41,665,554 | -0.97% | 81 | 1.18% | 87 | -9.38% | 54 | 8.00% |
| Dec 31, 2024 | 170 | -11.92% | 38,152,884 | -12.63% | 75 | 1.02% | 92 | -3.16% | 46 | -9.80% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2.94M | 5.94% | - |
| JPMorgan Small Cap Growth A | 1.58M | 3.13% | -97.11K |
| Vanguard Total Stock Mkt Idx Inv | 1.43M | 2.82% | - |
| Vanguard US Total Market Shares ETF | 1.40M | 2.80% | - |
| iShares Russell 2000 ETF | 1.13M | 2.23% | 257.32K |
| State Street® SPDR® S&P® Biotech ETF | 1.01M | 2.00% | -5.46K |
| SPDR® S&P Biotech ETF | 738.99K | 1.46% | 1.65K |
| Invesco S&P 500 ETF | 731.22K | 1.45% | 731.22K |
| Vanguard Small Cap Index | 561.89K | 1.13% | 3.30K |
| Vanguard Institutional Extnd Mkt Idx Tr | 515.55K | 1.02% | 2.61K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 10, 2026 | PAKOLA STEVE | Chief Medical Officer | Sell | $53.03K |
| Oct 09, 2025 | Simpson Curran | Chief Executive Officer | Sell | $262.63K |
| Sep 29, 2025 | Simpson Curran | Chief Executive Officer | Sell | $76.47K |
| Sep 10, 2025 | Simpson Curran | Chief Executive Officer | Sell | $77.49K |
| May 12, 2025 | Mills Kenneth T. | - | Sell | $163.05K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 1 |
| 2025 Q4 | - | 1 |
| 2025 Q3 | - | 2 |
| 2025 Q2 | - | 1 |
| 2025 Q1 | - | - |
RGNX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools